Adjuvant systemic therapy for breast cancer

Detalhes bibliográficos
Autor(a) principal: Cavalheiro, José Antônio
Data de Publicação: 2022
Outros Autores: H. Menke, Carlos, V. Biazús, Jorge, L. Xavier, Nilton, G. Rabin, Eliane, Cericatto, Rodrigo, C. Bittelbrunn, Ana
Tipo de documento: Artigo
Idioma: por
Título da fonte: Clinical and Biomedical Research
Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/125892
Resumo: Since the 1970s, substantial progress has been made in the understanding of the biology of breast cancer, on diagnostic approaches, and in determination of risk factors. This progress has been associated with advancements in the efficacy of treatments. Currently, many patients are receiving treatments that used to be reserved for cases with metastases. Clinical, multi-centered trials carried out by different authors have allowed for a continuous reevaluation of the basis of knowledge and recommendations of adjuvant therapy. Breast cancer, in this sense, is now understood as a systemic disease, which corroborates the use of systemic therapy in early breast cancer.
id UFRGS-20_843aaa796a3bd3f514314dfbad364153
oai_identifier_str oai:seer.ufrgs.br:article/125892
network_acronym_str UFRGS-20
network_name_str Clinical and Biomedical Research
repository_id_str
spelling Adjuvant systemic therapy for breast cancerTratamento sistêmico adjuvante em câncer de mamaQuimioterapiahormonioterapiaterapia sistêmicafatores prognósticosChemotherapyhormone therapysystemic therapyprognostic factorsSince the 1970s, substantial progress has been made in the understanding of the biology of breast cancer, on diagnostic approaches, and in determination of risk factors. This progress has been associated with advancements in the efficacy of treatments. Currently, many patients are receiving treatments that used to be reserved for cases with metastases. Clinical, multi-centered trials carried out by different authors have allowed for a continuous reevaluation of the basis of knowledge and recommendations of adjuvant therapy. Breast cancer, in this sense, is now understood as a systemic disease, which corroborates the use of systemic therapy in early breast cancer.Um significativo progresso no conhecimento e compreensão da biologia do câncer de mama, dos métodos diagnósticos e da determinação dos fatores de risco ocorreu desde os anos 70, acompanhado de avanços na eficácia dos tratamentos. Hoje, muitas pacientes recebem tratamentos anteriormente reservados para casos metastáticos. Os ensaios clínicos multicêntricos desenvolvidos por diferentes grupos permitem uma contínua reavaliação das bases de conhecimento e indicações de tratamento adjuvante. O câncer de mama deixou de ser considerado loco-regional e é reconhecido como sistêmico desde o seu início, o que sustenta o uso de terapia sistêmica em casos iniciais.HCPA/FAMED/UFRGS2022-07-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed Article"A Convite dos Editoresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/125892Clinical & Biomedical Research; Vol. 21 No. 2 (2001): Revista HCPAClinical and Biomedical Research; v. 21 n. 2 (2001): Revista HCPA2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSporhttps://seer.ufrgs.br/index.php/hcpa/article/view/125892/85524http://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessCavalheiro, José Antônio H. Menke, Carlos V. Biazús, Jorge L. Xavier, Nilton G. Rabin, Eliane Cericatto, Rodrigo C. Bittelbrunn, Ana 2022-07-18T19:41:10Zoai:seer.ufrgs.br:article/125892Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2022-07-18T19:41:10Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.none.fl_str_mv Adjuvant systemic therapy for breast cancer
Tratamento sistêmico adjuvante em câncer de mama
title Adjuvant systemic therapy for breast cancer
spellingShingle Adjuvant systemic therapy for breast cancer
Cavalheiro, José Antônio
Quimioterapia
hormonioterapia
terapia sistêmica
fatores prognósticos
Chemotherapy
hormone therapy
systemic therapy
prognostic factors
title_short Adjuvant systemic therapy for breast cancer
title_full Adjuvant systemic therapy for breast cancer
title_fullStr Adjuvant systemic therapy for breast cancer
title_full_unstemmed Adjuvant systemic therapy for breast cancer
title_sort Adjuvant systemic therapy for breast cancer
author Cavalheiro, José Antônio
author_facet Cavalheiro, José Antônio
H. Menke, Carlos
V. Biazús, Jorge
L. Xavier, Nilton
G. Rabin, Eliane
Cericatto, Rodrigo
C. Bittelbrunn, Ana
author_role author
author2 H. Menke, Carlos
V. Biazús, Jorge
L. Xavier, Nilton
G. Rabin, Eliane
Cericatto, Rodrigo
C. Bittelbrunn, Ana
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Cavalheiro, José Antônio
H. Menke, Carlos
V. Biazús, Jorge
L. Xavier, Nilton
G. Rabin, Eliane
Cericatto, Rodrigo
C. Bittelbrunn, Ana
dc.subject.por.fl_str_mv Quimioterapia
hormonioterapia
terapia sistêmica
fatores prognósticos
Chemotherapy
hormone therapy
systemic therapy
prognostic factors
topic Quimioterapia
hormonioterapia
terapia sistêmica
fatores prognósticos
Chemotherapy
hormone therapy
systemic therapy
prognostic factors
description Since the 1970s, substantial progress has been made in the understanding of the biology of breast cancer, on diagnostic approaches, and in determination of risk factors. This progress has been associated with advancements in the efficacy of treatments. Currently, many patients are receiving treatments that used to be reserved for cases with metastases. Clinical, multi-centered trials carried out by different authors have allowed for a continuous reevaluation of the basis of knowledge and recommendations of adjuvant therapy. Breast cancer, in this sense, is now understood as a systemic disease, which corroborates the use of systemic therapy in early breast cancer.
publishDate 2022
dc.date.none.fl_str_mv 2022-07-18
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article"
A Convite dos Editores
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/125892
url https://seer.ufrgs.br/index.php/hcpa/article/view/125892
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/125892/85524
dc.rights.driver.fl_str_mv http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv HCPA/FAMED/UFRGS
publisher.none.fl_str_mv HCPA/FAMED/UFRGS
dc.source.none.fl_str_mv Clinical & Biomedical Research; Vol. 21 No. 2 (2001): Revista HCPA
Clinical and Biomedical Research; v. 21 n. 2 (2001): Revista HCPA
2357-9730
reponame:Clinical and Biomedical Research
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Clinical and Biomedical Research
collection Clinical and Biomedical Research
repository.name.fl_str_mv Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv ||cbr@hcpa.edu.br
_version_ 1799767057450926080

Registros relacionados